We are live on ! Find out more
PHIO icon

Phio Pharmaceuticals
PHIO

14 hedge funds and large institutions have $1.34M invested in Phio Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

62% more capital invested

Capital invested by funds: $827K → $1.34M (+$516K)

56% more funds holding

Funds holding: 9 → 14 (+5)

7% more call options, than puts

Call options by funds: $570K | Put options by funds: $531K

0.01% less ownership

Funds ownership: 0.05% → 0.03% (-0.01%)

Holders
14
Holders Change
+5
Holders Change %
+55.56%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
5
Reduced
1
Closed
2
Calls
$570K
Puts
$531K
Net Calls
+$39K
Net Calls Change
+$39K

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$207K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$152K
3
GCP
GSA Capital Partners
United Kingdom
+$95.1K
4
Citadel Advisors
Citadel Advisors
Florida
+$71.5K
5
SM
Sabby Management
Florida
+$70.8K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Advisers
Two Sigma Advisers
New York
-$118K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$37.2K
3
UBS Group
UBS Group
Switzerland
-$15K
Name Holding Trade Value Shares
Change 		Change in
Stake
GCP
1
GSA Capital Partners
United Kingdom
$355K +$95.1K +286 +30%
Vanguard Group
2
Vanguard Group
Pennsylvania
$329K +$152K +456 +67%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$234K +$207K +622 +331%
Dimensional Fund Advisors
4
Dimensional Fund Advisors
Texas
$93K +$29.6K +89 +38%
Two Sigma Advisers
5
Two Sigma Advisers
New York
$79K -$118K -354 -56%
SM
6
Sabby Management
Florida
$62K +$70.8K +213 New
Citadel Advisors
7
Citadel Advisors
Florida
$62K +$71.5K +215 New
SFI
8
Susquehanna Fundamental Investments
Pennsylvania
$48K +$54.9K +165 New
VF
9
Virtu Financial
New York
$42K +$47.9K +144 New
JP Morgan Chase
10
JP Morgan Chase
New York
$14K +$15.6K +47 +2,350%
VFA
11
Valeo Financial Advisors
Indiana
$11K +$12.3K +37 New
SWM
12
Spire Wealth Management
Virginia
$6K +$6.32K +19 New
Morgan Stanley
13
Morgan Stanley
New York
$4K – – –
TCWM
14
Total Clarity Wealth Management
Illinois
$4K +$4.65K +14 New
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
– -$37.2K -112 Closed
UBS Group
16
UBS Group
Switzerland
– -$15K -52 Closed

PHIO Hedge Fund Activity: Q1 2021 in Review

14 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q1 2021, worth a combined $1.34M — up 62% from $827K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new PHIO positions and 2 closed out — a net gain of 5 holders — while 5 added to existing stakes and 1 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $207K. The largest seller was Two Sigma Advisers, cutting an estimated $118K.

  • 14 institutional investors held Phio Pharmaceuticals (PHIO) as of Q1 2021, up from 9 in Q4 2020.
  • Funds reported $1.34M of Phio Pharmaceuticals stock for Q1 2021, up 62% quarter-over-quarter.
  • 7 funds opened new Phio Pharmaceuticals positions in Q1 2021 and 2 closed out, a net change of +5 holders.
  • The largest Phio Pharmaceuticals buyer in Q1 2021 was Geode Capital Management, an estimated $207K added.
  • The largest Phio Pharmaceuticals seller in Q1 2021 was Two Sigma Advisers, an estimated $118K sold.

Based on aggregated 13F filings for Q1 2021.